<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617669</url>
  </required_header>
  <id_info>
    <org_study_id>D4320C00033</org_study_id>
    <nct_id>NCT00617669</nct_id>
  </id_info>
  <brief_title>A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer</brief_title>
  <acronym>ENTHUSE M1C</acronym>
  <official_title>A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 (Zibotentan) in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enthuse M1C is a large phase III clinical trial studying the safety and efficacy of ZD4054
      (Zibotentan) in combination with docetaxel (Taxotere) in patients with metastatic hormone
      resistant prostate cancer (HRPC).

      This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can
      further improve survival compared with docetaxel alone.

      ZD4054 (Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread
      by blocking Endothelin A receptor activity. This trial will look at the effects of ZD4054
      (Zibotentan) in hormone resistant prostate cancer patients with bone metastases compared with
      docetaxel.

      All patients participating in this clinical trial will receive docetaxel chemotherapy, which
      is a commonly used chemotherapy to treat prostate cancer in addition to other existing
      prostate cancer therapies.

      Half the patients will receive ZD4054 (Zibotentan), and half the patients will receive
      placebo in addition to docetaxel and other prostate cancer therapy. By participating in this
      trial there is a 50% chance that patients will receive an agent that may further slow the
      progression of the tumour.

      No patients will be deprived of standard prostate cancer therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Patients were followed for survival up to 40 months</time_frame>
    <description>Median time (in months) from randomisation until death using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Patients were followed for progression up to 40 months</time_frame>
    <description>Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method. Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Skeletal Related Events</measure>
    <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
    <description>Median time (in months) from randomisation until occurrence of a skeletal related event using the Kaplan-Meier method, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Prostate-specific Antigen (PSA) Progression</measure>
    <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
    <description>Median time (in months) from randomisation until first PSA value &gt;50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pain Progression</measure>
    <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
    <description>Median time (in months) from randomisation until date of first assessment of increased pain using the Kaplan-Meier method, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Response</measure>
    <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
    <description>Number of patients with a pain response, defined as a decrease in brief pain inventory questionnaire (BPI) of at least 2 points from baseline or a decrease in opiate use of 25% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
    <description>Median time (in months) from randomisation until deterioration of Health Related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Response</measure>
    <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
    <description>PSA response defined as &gt;50% decrease in serum PSA values from baseline seen in at least 2 consecutive PSA values at least 2 weeks apart.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1494</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo + Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZD4054 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>intravenous infusion given every three weeks</description>
    <arm_group_label>Placebo + Docetaxel</arm_group_label>
    <arm_group_label>ZD4054 + Docetaxel</arm_group_label>
    <other_name>Taxotere®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD4054</intervention_name>
    <description>10 mg oral once daily dose</description>
    <arm_group_label>ZD4054 + Docetaxel</arm_group_label>
    <other_name>Zibotentan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo oral tablet once daily</description>
    <arm_group_label>Placebo + Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who answer TRUE to the following criteria may be eligible to participate in this
        trial.

          -  Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has
             spread to the bone (bone metastasis)

          -  Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment

          -  Currently receiving treatment with surgical or medical castration

        Exclusion Criteria:

        Patients who answer TRUE to the following ARE NOT eligible to participate in this trial.

          -  Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior
             targeted cancer therapies are permitted if received during a previous clinical trial.

          -  Suffering from heart failure or had a myocardial infarction within last 6 months

          -  A history of epilepsy or seizures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Fizazi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judd W Moul, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>PORTUGALt St. Lucie</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bahia Blanca</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashford</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara/ LA</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiania</city>
        <state>Goias/ LA</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas GERMANYais</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <state>Parana/ Brazil</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Londrina</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>PORTUGALto Alegre</city>
        <state>Rio Grande do Sul/ LA</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo/ LA</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <state>CZECHOSLOVAKIA Republic</state>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kromeriz</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague 6</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Usti nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seinajoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Roche sur Yon</city>
        <state>FRANCEnce</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <state>FRANCEnce</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <state>FRANCEnce</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reims</city>
        <state>FRANCEnce</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <state>FRANCEnce</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <state>GERMANYmany</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Emmendingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kirchheim-Teck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Luebeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <state>HUNGARYary</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <state>HUNGARYary</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <state>HUNGARYary</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ny Regyh Za</city>
        <state>HUNGARYary</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <state>HUNGARYary</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bhopal</city>
        <state>Madhya Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bikaner</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkota</city>
        <state>West Bengal</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genoa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lugo (RA)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju</city>
        <state>Chungbuk</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ilsandong-gu, Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nowon-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cercado de Arequipa</city>
        <state>Arequipa</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cercado</city>
        <state>Arequipa</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Callao</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <state>POLANDand</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swidnica</city>
        <state>POLANDand</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszaa</city>
        <state>POLANDand</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koscierzyna</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbra</city>
        <state>PORTUGALtugal</state>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>PORTUGALto</city>
        <state>PORTUGALtugal</state>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barnaul</city>
        <state>RUSSIAsia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izhevsk</city>
        <state>RUSSIAsia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kursk</city>
        <state>RUSSIAsia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sochi</city>
        <state>RUSSIAsia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voronezh</city>
        <state>RUSSIAsia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <state>SERBIAbia</state>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beograd</city>
        <state>SERBIAbia</state>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <state>SERBIAbia</state>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panorama</city>
        <state>Cape Town</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>TyGERberg</city>
        <state>Cape Town</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overport</city>
        <state>Durban</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>PORt Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Locarno</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sursee</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <state>TAIWANwan</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>TAIWANpei</city>
        <state>TAIWANwan</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westgate Road</city>
        <state>Newcastle Upon Tyne</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Norway</country>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <results_first_submitted>April 26, 2012</results_first_submitted>
  <results_first_submitted_qc>April 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 31, 2012</results_first_posted>
  <last_update_submitted>September 4, 2012</last_update_submitted>
  <last_update_submitted_qc>September 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone Resistant Prostate Cancer</keyword>
  <keyword>Endothelin A Receptor Antagonist</keyword>
  <keyword>Endothelin A</keyword>
  <keyword>Endothelin A antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Endothelin A Receptor Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1494 patients with hormone resistant prostate cancer patients and bone metastasis were recruited between 24th January 2008 and 10th May 2011</recruitment_details>
      <pre_assignment_details>442 of the 1494 enrolled patients were not randomised to treatment groups as they failed screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ZD4054 + Docetaxel</title>
          <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Docetaxel</title>
          <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="524"/>
                <participants group_id="P2" count="528"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Who Received IP</title>
              <participants_list>
                <participants group_id="P1" count="522"/>
                <participants group_id="P2" count="525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94">Patients receiving ZD4054 10 mg at data cut-off</participants>
                <participants group_id="P2" count="77">Patients receiving placebo at data cut-off</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="430"/>
                <participants group_id="P2" count="451"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not otherwise captured, eg; death</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
                <participants group_id="P2" count="290"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patients randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ZD4054 + Docetaxel</title>
          <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Docetaxel</title>
          <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="524"/>
            <count group_id="B2" value="528"/>
            <count group_id="B3" value="1052"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="67.7"/>
                    <measurement group_id="B2" value="7.8" spread="67.6"/>
                    <measurement group_id="B3" value="7.9" spread="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="524"/>
                    <measurement group_id="B2" value="528"/>
                    <measurement group_id="B3" value="1052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Median time (in months) from randomisation until death using the Kaplan-Meier method.</description>
        <time_frame>Patients were followed for survival up to 40 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ZD4054 + Docetaxel</title>
            <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Docetaxel</title>
            <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Median time (in months) from randomisation until death using the Kaplan-Meier method.</description>
          <population>Full Analysis Set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="11.6" upper_limit="32.0"/>
                    <measurement group_id="O2" value="19.2" lower_limit="12.0" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method. Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline</description>
        <time_frame>Patients were followed for progression up to 40 months</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ZD4054 + Docetaxel</title>
            <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Docetaxel</title>
            <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method. Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline</description>
          <population>Full Analysis Set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="3.5" upper_limit="13.1"/>
                    <measurement group_id="O2" value="7.9" lower_limit="4.0" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Skeletal Related Events</title>
        <description>Median time (in months) from randomisation until occurrence of a skeletal related event using the Kaplan-Meier method, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression.</description>
        <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ZD4054 + Docetaxel</title>
            <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Docetaxel</title>
            <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Skeletal Related Events</title>
          <description>Median time (in months) from randomisation until occurrence of a skeletal related event using the Kaplan-Meier method, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression.</description>
          <population>Full Analysis Set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="10.0" upper_limit="25.3"/>
                    <measurement group_id="O2" value="17.3" lower_limit="10.3" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Prostate-specific Antigen (PSA) Progression</title>
        <description>Median time (in months) from randomisation until first PSA value &gt;50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.</description>
        <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ZD4054 + Docetaxel</title>
            <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Docetaxel</title>
            <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Prostate-specific Antigen (PSA) Progression</title>
          <description>Median time (in months) from randomisation until first PSA value &gt;50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="6.2" upper_limit="19.6"/>
                    <measurement group_id="O2" value="12.1" lower_limit="6.0" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pain Progression</title>
        <description>Median time (in months) from randomisation until date of first assessment of increased pain using the Kaplan-Meier method, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.</description>
        <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ZD4054 + Docetaxel</title>
            <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Docetaxel</title>
            <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pain Progression</title>
          <description>Median time (in months) from randomisation until date of first assessment of increased pain using the Kaplan-Meier method, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.</description>
          <population>Full Analysis Set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="3.9" upper_limit="18.4"/>
                    <measurement group_id="O2" value="10.0" lower_limit="4.2" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Response</title>
        <description>Number of patients with a pain response, defined as a decrease in brief pain inventory questionnaire (BPI) of at least 2 points from baseline or a decrease in opiate use of 25% from baseline.</description>
        <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
        <population>The Pain Response Analysis Set includes patients who were either receiving opiates at baseline (randomisation) or with a baseline BPI score ≥2.</population>
        <group_list>
          <group group_id="O1">
            <title>ZD4054 + Docetaxel</title>
            <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Docetaxel</title>
            <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Response</title>
          <description>Number of patients with a pain response, defined as a decrease in brief pain inventory questionnaire (BPI) of at least 2 points from baseline or a decrease in opiate use of 25% from baseline.</description>
          <population>The Pain Response Analysis Set includes patients who were either receiving opiates at baseline (randomisation) or with a baseline BPI score ≥2.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life</title>
        <description>Median time (in months) from randomisation until deterioration of Health Related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.</description>
        <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ZD4054 + Docetaxel</title>
            <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Docetaxel</title>
            <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life</title>
          <description>Median time (in months) from randomisation until deterioration of Health Related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.</description>
          <population>Full Analysis Set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="1.6" upper_limit="10.7"/>
                    <measurement group_id="O2" value="5.1" lower_limit="2.1" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PSA Response</title>
        <description>PSA response defined as &gt;50% decrease in serum PSA values from baseline seen in at least 2 consecutive PSA values at least 2 weeks apart.</description>
        <time_frame>While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ZD4054 + Docetaxel</title>
            <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Docetaxel</title>
            <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Response</title>
          <description>PSA response defined as &gt;50% decrease in serum PSA values from baseline seen in at least 2 consecutive PSA values at least 2 weeks apart.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279"/>
                    <measurement group_id="O2" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ZD4054 + Docetaxel</title>
          <description>XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Docetaxel</title>
          <description>placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="203" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lymphatic Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Aortic Valve Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Diastolic Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypertrophic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Adrenocortical Insufficiency Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Inappropriate Antidiuretic Hormone Secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Scleral Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Staphyloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Colitis Ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Colonic Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Diarrhoea Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Erosive Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia Strangulated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Intestinal Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Irritable Bowel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Large Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Mouth Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Neutropenic Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Oesophagitis Ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Rectourethral Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Medical Device Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Device Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Arthritis Infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bacterial Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Catheter Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lyme Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Necrotising Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Neutropenic Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Peritonitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pneumocystis Jiroveci Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Psoas Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Staphylococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage Traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Kidney Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Radiation Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Stress Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Toxicity To Various Agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Blood Electrolytes Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT Prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis Of Jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bladder Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Stromal Tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lentigo Maligna Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Malignant Lymphoid Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Depressed Level Of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Diabetic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bladder Neck Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bladder Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cystitis Noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Haemorrhage Urinary Tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Postrenal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Renal Tubular Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bronchitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pleural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Jugular Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Femoral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypovolaemic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>sThrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="490" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="483" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 14.0">Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="278" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nail Discolouration</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nail Disorder</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>3. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.
AstraZeneca can review results communications prior to public release and may within 60 days of receipt require amendments to be made. AstraZeneca can also require that submission or disclosure be delayed to allow for</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

